ALCAM and arthritic joint disease: Importantly, the ALCAM/CD6 co-stimulatory pathway has been implicated in collagen-induced arthritis and other models of autoimmunity (52, 53), and phase 1 clinical trials with anti-CD6 monoclonal antibody therapy in RA patients produced encouraging results (42, 43).